Auteur/autrice : admin

Comprehensive reflex biomarker testing for appropriate patient identification

ESMO 2022

Bonus. For supervision of research and PhD (PEDR)

Grant. NIRAPK study. Ligue contre le cancer: 40,000 euros

Funding. Early phase trial CLIP2, Institut National du Cancer. IMMUNOGAST: An umbrella phase 2 trial to assess personalized targeted IMMUNOtherapy-based regimens in recurrent advanced/metastatic GASTric adenocarcinoma patients. Amount: 500,000 euros.

Funding. TROPHAMET: a phase II trial with safety run-in of Avelumab and METhotrexate in low-risk gestational TROPHoblastic neoplasia as first line treatment. Amount: 800,000 euros.

Funding. ONCOPRO: Predictive value of progastrin titer at diagnosis and of progastrin kinetics during treatment in cancer patients. Amount: 1.6 Millions Euros